{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:48:58Z","timestamp":1786373338999,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["107-2314-B-038-019-MY3"],"award-info":[{"award-number":["107-2314-B-038-019-MY3"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["109TMU-TMUH-22"],"award-info":[{"award-number":["109TMU-TMUH-22"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["TMU109-AE1-B08"],"award-info":[{"award-number":["TMU109-AE1-B08"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["IIT-1072-7"],"award-info":[{"award-number":["IIT-1072-7"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>Patients with kidney failure have a high risk of cardiovascular disease due to cardiac remodeling, left ventricular fibrosis, and hyperaldosteronism, all of which can be potentially mitigated by mineralocorticoid receptor antagonists. However, because of the fear of hyperkalemia, the use of mineralocorticoid receptor antagonists in patients with kidney failure is limited in current clinical practice, and few studies have investigated the efficacy and safety. Thus, we aimed to determine the benefits and side effects of mineralocorticoid receptor antagonists in patients with kidney failure treated with dialysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>This is a systematic review and meta-analysis of randomized controlled trials published from 2005 to 2020 that compared the effect of mineralocorticoid receptor antagonists with either placebo or no treatment in patients with kidney failure. Two reviewers independently searched the PubMed, EMBASE, and Cochrane databases for all published studies, extracted data, assessed the risk of bias, and rated the quality of evidence. A meta-analysis was conducted on 14 eligible randomized controlled trials, and a total of 1309 patients were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      High-quality evidence suggested that mineralocorticoid receptor antagonists are associated with lower cardiovascular mortality (relative risk, 0.41; 95% confidence interval, 0.24 to 0.70;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.001) and all-cause mortality (relative risk, 0.44; 95% confidence interval, 0.30 to 0.66;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), and the risk of hyperkalemia was comparable with that of control group (relative risk, 1.12; 95% confidence interval, 0.91 to 1.36;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.29). However, no significant decrease in nonfatal cardiovascular events and stroke was observed, and there was no significant improvement in BP or cardiac performance parameters, including left ventricular ejection fraction and left ventricular mass index.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our meta-analysis suggests that mineralocorticoid receptor antagonists might improve clinical outcomes of patients with kidney failure without significant increase in the risk of hyperkalemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.15841020","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T16:35:14Z","timestamp":1623429314000},"page":"916-925","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis"],"prefix":"10.2215","volume":"16","author":[{"given":"Kuan-Ting","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-No","family":"Kang","sequence":"additional","affiliation":[{"name":"Institute of Health Policy and Management, College of Public Health, National Taiwan University, Taipei, Taiwan"},{"name":"Evidence-Based Medicine Center, Wan Fang Hospital, Taipei Medical University"},{"name":"Cochrane Taiwan, Taipei Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Chung","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Taipei Medical University-Research Center of Urology and Kidney (TMU-RCUK), School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Lin","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chiao","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan"},{"name":"Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, School of Pharmacy, Taipei Medical University, Taipei, Taiwan"},{"name":"Integrative Research Center for Critical Care, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan"},{"name":"Department of Medical Research, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Chao","family":"Fang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Taipei Medical University-Research Center of Urology and Kidney (TMU-RCUK), School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai-Szu","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Taipei Medical University-Research Center of Urology and Kidney (TMU-RCUK), School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3194-2204","authenticated-orcid":false,"given":"Chih-Chin","family":"Kao","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Division of Nephrology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Taipei Medical University-Research Center of Urology and Kidney (TMU-RCUK), School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6]]},"reference":[{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: A systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/ki.1995.132","article-title":"Congestive heart failure in dialysis patients: Prevalence, incidence, prognosis and risk factors","volume":"47","author":"Harnett","year":"1995","journal-title":"Kidney Int"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ijcard.2014.06.062","article-title":"Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease","volume":"176","author":"Charytan","year":"2014","journal-title":"Int J Cardiol"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11906-017-0737-y","article-title":"Mineralocorticoid receptor blockade in end-stage renal disease","volume":"19","author":"Lyubarova","year":"2017","journal-title":"Curr Hypertens Rep"},{"key":"B6-20241015","first-page":"62","article-title":"Cardiac remodeling: Concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment","volume":"106","author":"Azevedo","year":"2016","journal-title":"Arq Bras Cardiol"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"Am J Cardiol"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s11255-016-1319-7","article-title":"Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: A systematic review and meta-analysis","volume":"48","author":"Lu","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"B11-20241015","first-page":"45","article-title":"Effects of spironolactone on cardiovascular complications in hemodialysis patients of taleghani hospital during the period of 2016-2017: A randomized double-blind controlled clinical trial","volume":"20","author":"Ziaee","year":"2019","journal-title":"Iranian Heart J"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): A randomized, placebo-controlled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jch.12628","article-title":"Long-term effects of low-dose spironolactone on chronic dialysis patients: A randomized placebo-controlled study","volume":"18","author":"Lin","year":"2016","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.2215\/CJN.12371214","article-title":"The safety of eplerenone in hemodialysis patients: A noninferiority randomized controlled trial","volume":"10","author":"Walsh","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","article-title":"Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients","volume":"63","author":"Matsumoto","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1681\/ASN.2013030273","article-title":"Long-term effects of spironolactone in peritoneal dialysis patients","volume":"25","author":"Ito","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B18-20241015","first-page":"507","article-title":"A prospective double-blind randomized placebo-controlled clinical trial to evaluate the safety and efficacy of spironolactone in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis","volume":"23","author":"Taheri","year":"2012","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B20-20241015","first-page":"392","article-title":"Spironolactone in chronic hemodialysis patients improves cardiac function","volume":"20","author":"Taheri","year":"2009","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2016.04.011","article-title":"The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: A systematic review and meta-analysis","volume":"68","author":"Quach","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines. 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1753944715591448","article-title":"Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients","volume":"9","author":"Feniman-De-Stefano","year":"2015","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/jch.12374","article-title":"Effects of spironolactone on dialysis patients with refractory hypertension: A randomized controlled study","volume":"16","author":"Ni","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B27-20241015","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"B28-20241015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/1744-9987.12219","article-title":"Randomized, double-blind, placebo-controlled trial of spironolactone for hypokalemia in continuous ambulatory peritoneal dialysis patients","volume":"19","author":"Yongsiri","year":"2015","journal-title":"Ther Apher Dial"},{"key":"B30-20241015","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B31-20241015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: A systematic review of randomized clinical trials","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur Heart J"},{"key":"B32-20241015","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000435838","article-title":"Left ventricular hypertrophy in chronic kidney disease patients: From pathophysiology to treatment","volume":"5","author":"Di Lullo","year":"2015","journal-title":"Cardiorenal Med"},{"key":"B33-20241015","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/ndt\/gfl752","article-title":"No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients","volume":"22","author":"Han","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"B34-20241015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-6386(86)80120-2","article-title":"Increased secretion of potassium in the rectum of humans with chronic renal failure","volume":"8","author":"Martin","year":"1986","journal-title":"Am J Kidney Dis"},{"key":"B35-20241015","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.ebiom.2015.10.027","article-title":"The colon as the potassium target: Entering the colonic age of hyperkalemia treatment?","volume":"2","author":"Batlle","year":"2015","journal-title":"EBioMedicine"},{"key":"B36-20241015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1042\/cs0710393","article-title":"Enhanced rectal potassium secretion in chronic renal insufficiency: Evidence for large intestinal potassium adaptation in man","volume":"71","author":"Sandle","year":"1986","journal-title":"Clin Sci (Lond)"},{"key":"B37-20241015","first-page":"F275","article-title":"Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure","volume":"274","author":"Hatch","year":"1998","journal-title":"Am J Physiol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.15841020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:57Z","timestamp":1786369497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.15841020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.15841020","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"2020-10-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}